https://www.thebodypro.com/category/hiv-care-continuum/tag/neurocognitive
HIV Care Continuum

Neurocognitive

The Latest

raising the bar

This Week in HIV Research: Setting a New Bar

June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.

By Barbara Jungwirth and Myles Helfand
close up of cannabis plant

This Week in HIV Research: More Answers—and Questions—on Cannabis Use

Jan. 23, 2020: Neurocognitive benefits of cannabis use; how unquantifiable HIV in CSF correlates to executive function; updated findings on efavirenz and microcephaly; cost-efficacy of a specialized HIV care coordination team.

By Barbara Jungwirth and Myles Helfand
woman's hand using phone

This Week in HIV Research: Just a Text Away

Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.

By Barbara Jungwirth and Myles Helfand
hand reaching

This Week in HIV Research: Where Our Reach Falls Short

Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.

By Barbara Jungwirth and Myles Helfand
many maps overlapping

This Week in HIV Research: New Explorations of Antiretroviral Adherence

Nov. 14, 2019: Psychiatric disorders, adherence, and viral suppression; depression and adherence among women with HIV; using hair to link food insecurity and HIV viremia; a point-of-care test for tenofovir adherence.

By Barbara Jungwirth and Myles Helfand
hole in a fence

This Week in HIV Research: Removing Barriers to Better Care

Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.

By Barbara Jungwirth and Myles Helfand
neon heart

This Week in HIV Research: New Insights Into Cardiovascular Risk

Oct. 3, 2019: The sexual divide in HIV-related heart disease; weight gain among women on integrase inhibitors; HIV's association with non-specific health conditions; hopeful trends in self-reported neurocognitive impairment.

By Barbara Jungwirth and Myles Helfand
Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors Img

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
Promo Image

This Week in HIV Research: HIV Is Not an Obstacle

April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.

By Barbara Jungwirth and Myles Helfand
Promo Image

This Week in HIV Research: The Clinical Impacts of HIV Stigma

Internalized HIV stigma, depression, and adherence in women; what “internalized HIV stigma” actually means; tenofovir-containing gel and genital herpes prevention; the neurocognitive effects of cerebrospinal HIV escape.

By Barbara Jungwirth and Myles Helfand